|MDACC Study No:||RTOG0825 (clinicaltrials.gov NCT No: NCT00884741)|
|Title:||PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS BEVACIZUMAB VERSUS CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA|
|Principal Investigator:||Mark R. Gilbert|
|Treatment Agent:||Bevacizumab; Irinotecan; Temozolomide|
|Study Description:||The goal of this clinical research study is to find out if adding bevacizumab |
to the combination of temozolomide and radiation will help to control
glioblastoma better than treatment with temozolomide and radiation alone.
Researchers will study if the genetic pattern in the tumor cells is related to
each participant's response to the bevacizumab and the overall outcome. The
safety of these 2 combination treatments will also be studied.